Screening for Bladder Cancer

NCT ID: NCT00848627

Last Updated: 2020-02-25

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 197 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2007-03-31
• Study Completion Date: 2012-02-29

Brief Summary

In the study proposed, up to 1,500 men age 60 and over with strong smoking histories will test their urine for the presence of blood daily for two 10-day testing periods with the Ames Hemastix. Individuals with even a solitary positive test will undergo a thorough urologic evaluation to determine the cause of hematuria and follow-up will continue for 2 years after completion of the study.

Detailed Description

Reduction of cancer mortality is a stated goal of the National Cancer Institute. Cancer of the bladder is the 4th most commonly diagnosed cancer and 7th leading cause of cancer death in the American men, and represents an important target for mortality-reducing efforts. Furthermore, these tumors, even in early (i.e. curable) stages, usually cause several easily detectable abnormalities, including hematuria, and the presence of abnormal tumor products that are shed into urine or lie within exfoliated malignant cells.

The overall goal of the proposed study is to gain information concerning the performance characteristics of three bladder cancer markers when combined with hematuria testing in detecting bladder cancer.

A mail back questionnaire, completed at the beginning of the study, will provide information about the participants and the results of testings will be reported after each testing period. Individuals with even a solitary positive test will undergo a thorough urologic evaluation to determine the cause of hematuria and follow-up will continue or 2 years after completion of the study. At the time of the evaluation, three bladder cancer marker tests, NMP22 Bladder Chek, ImmunoCyt and UroVysion FISH will be performed, but regardless of the results, a hematuria evaluation will be completed. Data will be updated continually.

The 10 day testing with Hemastix will be repeated 9 months after the first one is completed regardless of the outcome of the first testing.

Conditions

Bladder Cancer

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Males

60 years of age or older Smokers or history of smoking

Specimen and questionnaires only

Intervention Type: OTHER

Specimen and questionnaires only

Interventions

Specimen and questionnaires only

Specimen and questionnaires only

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Men age 60 and over, - who are current cigarette smokers OR - who have a history of at least 20 pack years smoking OR - who have over a 30 pack/year history who have stopped smoking within 10 years of the registration date OR - who have a 40 pack year history of smoking regardless of the quit date, will be eligible for participation.
• Patients with prostate or renal cancer must have been treated more than 5 years previously and be considered disease-free at the time of entry. In the case of prostate cancer, patients may have only received prostatectomy as their treatment and must have undetectable PSA's at study entry.
• In the case of calculus disease, patients must be believed to be stone free at time of study entry and could not have had a stone attack within the previous 2 years.
• Patients receiving anticoagulation therapy, such as Warfarin, Plavix, Lovenox, aspirin, etc. will be able to take part in the study and, will be thoroughly worked-up if the only explainable cause of hematuria is receiving anticoagulation medication.

Exclusion Criteria

• history of urothelial cancer
• any malignancy other than non-melanoma skin cancers treated within the past 5 years
• benign tumors of the urinary tract that are still existent
• known urinary calculi
• medical or oncological conditions known to produce hematuria (e.g. glomerulonephritis, treatments with cyclophosphamide, methotrexate and pelvic radiation therapy)
• visual, psychological, neurological, musculoskeletal, etc. impairments that would make home testing impractical

• Minimum Eligible Age: 60 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

M.D. Anderson Cancer Center

OTHER

Sponsor Role: collaborator

University of Rochester

OTHER

Sponsor Role: collaborator

Laval University

OTHER

Sponsor Role: collaborator

Baylor College of Medicine

OTHER

Sponsor Role: lead

Responsible Party

Seth Lerner

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Seth P. Lerner, MD

Role: PRINCIPAL_INVESTIGATOR

Baylor College of Medicine

Locations

University of Rochester Medical Center

Rochester, New York, United States

M.D. Anderson Cancer Center

Houston, Texas, United States

Laval University

Québec, Quebec, Canada

Countries

United States; Canada

Other Identifiers

5P50CA091846

Identifier Type: NIH

Identifier Source: secondary_id

View Link

H-20395

Identifier Type: -

Identifier Source: org_study_id

NCT00831558

Identifier Type: -

Identifier Source: nct_alias